{
    "name": "Borjeson-Forssman-Lehmann Syndrome",
    "slug": "borjeson-forssman-lehmann-syndrome",
    "aliases": [
        "BFLS",
        "Mental Retardation, Epilepsy, Gynecomastia Syndrome"
    ],
    "description": "Borjeson-Forssman-Lehmann Syndrome (BFLS) is a rare X-linked intellectual disability syndrome characterized by intellectual disability, epilepsy, endocrine abnormalities (gynecomastia in males, hypogonadism), characteristic facial features (large ears, ptosis), obesity, and short stature. The severity of symptoms can vary among affected individuals, even within the same family.",
    "category": "GENETIC",
    "icdCode": "Q87.8",
    "orphaCode": "127",
    "omimCode": "301900",
    "prevalence": "<1 / 1,000,000",
    "estimatedCases": 300,
    "ageOfOnset": "Infancy or Early Childhood",
    "inheritance": "X_LINKED",
    "symptoms": [
        "Intellectual disability (moderate to severe)",
        "Epilepsy (various seizure types)",
        "Gynecomastia (males)",
        "Hypogonadism (males)",
        "Obesity",
        "Short stature",
        "Characteristic facial features (large ears, ptosis, prominent supraorbital ridges)",
        "Tapered fingers and broad toes",
        "Learning disabilities",
        "Behavioral problems (hyperactivity, aggression, autism spectrum disorder)"
    ],
    "affectedSystems": [
        "Nervous System",
        "Endocrine System",
        "Skeletal System",
        "Reproductive System"
    ],
    "prognosis": "The prognosis varies depending on the severity of the symptoms and the effectiveness of management. Individuals with BFLS typically require lifelong support and care.",
    "lifeExpectancy": "Life expectancy may be shortened due to complications such as seizures or other medical conditions, but with appropriate management, many individuals can live into adulthood.",
    "diagnosticMethods": [
        "Clinical evaluation",
        "Physical examination",
        "Neurological assessment",
        "Endocrine evaluation (hormone levels)",
        "Genetic testing (sequencing of PHF6 gene)",
        "Brain MRI",
        "Electroencephalogram (EEG)"
    ],
    "treatmentOptions": [
        {
            "name": "Anti-epileptic medications",
            "type": "MEDICATION",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        },
        {
            "name": "Hormone replacement therapy (testosterone)",
            "type": "MEDICATION",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        },
        {
            "name": "Educational and behavioral therapy",
            "type": "THERAPY",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Physical therapy",
            "type": "THERAPY",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Occupational therapy",
            "type": "THERAPY",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Speech therapy",
            "type": "THERAPY",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Nutritional support and weight management",
            "type": "SUPPORTIVE",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Surgical management of gynecomastia",
            "type": "SURGERY",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": false,
            "approvalYear": null
        }
    ],
    "researchStatus": "OBSERVATIONAL",
    "clinicalTrialsCount": 0,
    "keyResearchCenters": [
        "National Institutes of Health (NIH)",
        "Academic medical centers with genetics departments"
    ],
    "patientOrganizations": [
        {
            "name": "National Organization for Rare Disorders (NORD)",
            "url": "https://rarediseases.org/",
            "country": "USA"
        },
        {
            "name": "Genetic and Rare Diseases Information Center (GARD)",
            "url": "https://rarediseases.info.nih.gov/",
            "country": "USA"
        }
    ],
    "relatedConditions": [
        "Fragile X Syndrome",
        "Prader-Willi Syndrome",
        "Angelman Syndrome",
        "Other X-linked intellectual disability syndromes"
    ],
    "specialistTypes": [
        "Clinical Geneticist",
        "Neurologist",
        "Endocrinologist",
        "Pediatrician",
        "Developmental Pediatrician",
        "Psychiatrist"
    ],
    "eli5Summary": "Borjeson-Forssman-Lehmann Syndrome is a rare problem that mostly affects boys. It makes it hard for them to learn, they might have seizures, and they can get bigger breasts. They also might be shorter and a bit chubby. Doctors can help with medicine and special classes.",
    "clinicalSummary": "Borjeson-Forssman-Lehmann Syndrome (BFLS) is a rare X-linked disorder caused by mutations in the PHF6 gene. This gene plays a crucial role in neuronal development and chromatin modification. Clinically, BFLS is characterized by moderate to severe intellectual disability, epilepsy (often with onset in infancy or early childhood), gynecomastia and hypogonadism in males, characteristic facial dysmorphisms, truncal obesity, and short stature. Neurological features may include hypotonia and delayed motor milestones. Behavioral problems such as hyperactivity, aggression, and autistic features are common. Diagnosis is typically confirmed through genetic testing identifying a pathogenic variant in PHF6. Management is primarily supportive, focusing on seizure control, hormone replacement therapy, educational and behavioral interventions, and weight management. The phenotypic spectrum can vary, and females carrying the mutation may exhibit milder symptoms.",
    "historicalBackground": "Borjeson-Forssman-Lehmann Syndrome was first described in 1962 by BÃ¶rjeson, Forssman, and Lehmann in a Swedish family. The genetic basis of the syndrome, mutations in the PHF6 gene, was identified in 2003.",
    "recentBreakthroughs": [
        {
            "year": 2022,
            "title": "Expanding the Phenotypic Spectrum of PHF6-related Disorders",
            "description": "Research continues to refine the understanding of the clinical variability associated with PHF6 mutations, including milder presentations in females and the identification of novel mutations.",
            "sourceUrl": null
        },
        {
            "year": 2023,
            "title": "Investigating the Role of PHF6 in Neuronal Development",
            "description": "Studies are ongoing to elucidate the precise mechanisms by which PHF6 mutations disrupt neuronal development and contribute to the cognitive and behavioral features of BFLS.",
            "sourceUrl": null
        }
    ],
    "heroImage": null,
    "diagrams": [],
    "lastUpdated": "2024-12-01",
    "reviewedBy": "MDRPedia Medical Team",
    "sources": [
        {
            "name": "Orphanet",
            "url": "https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=127"
        },
        {
            "name": "OMIM",
            "url": "https://www.omim.org/entry/301900"
        },
        {
            "name": "National Organization for Rare Disorders (NORD)",
            "url": "https://rarediseases.org/"
        }
    ]
}